Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Fortrea Holdings Inc.
FTRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$17.53
▼ -0.28%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.36 - $18.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 240.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Integrated two-segment model combining clinical expertise with proprietary technology solutions
- Flexible delivery models (full service, FSP, hybrid) enabling customized client partnerships
- Technology-enabled trial solutions that optimize patient recruitment, randomization, and drug supply efficiency
- Full-spectrum clinical development capabilities from Phase I through post-approval
- Scale and operational efficiency serving global pharmaceutical, biotech, and medical device markets
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Turning profitable
Increasing pharmaceutical industry outsourcing of clinical trial management to specialized CROs
Value
Fairly valued vs Biotech & Therapeutics peers
Momentum
Hot
+86.0% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying FTRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 5, 2026
Reported EPS of $0.16 vs $0.03 consensus (+433.3% surprise). Revenue of $636.5M vs $628.5M expected (+1.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+433.3%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
-10%
-2%
+7%
+4%
-5%
-2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$662.4M
$674.9M
$697.0M
$651.3M
$710.3M
$701.3M
$660.5M
$636.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-3.7%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
$16.00
▼ -8.7% vs $17.53
Latest: Mizuho · May 12, 2026
4 analysts covering